Want to see KR:005500 full AI Analyst Report?
Top Page
Samjin Pharmaceutical Co., Ltd.
(005500)
Select Model
Select Model
Rating:66Neutral
Price Target:
$20,855.00
Action:N/A
Date:10/28/26
The score is driven primarily by moderate financial performance—stable leverage and solid gross margins, but weakened operating profitability and historically volatile free cash flow. Valuation is a key positive (low P/E and strong dividend yield), while technicals are neutral with only modest momentum signals.
Positive Factors
Integrated pharmaceutical platform
Samjin combines research, development, manufacturing, and marketing across prescription and over-the-counter medicines. This integrated operating model can support product continuity, internal capabilities, and control over commercialization as the company develops and maintains its domestic portfolio.
Negative Factors
Negative operating profitability
The shift to slightly negative TTM operating income shows that gross profit is not currently translating into operating earnings. If this persists, cost pressure could limit internal funding for development and marketing while weakening the durability of the company’s earnings profile.
Read all positive and negative factors
Positive Factors
Negative Factors
Integrated pharmaceutical platform
Samjin combines research, development, manufacturing, and marketing across prescription and over-the-counter medicines. This integrated operating model can support product continuity, internal capabilities, and control over commercialization as the company develops and maintains its domestic portfolio.
Read all positive factors
Samjin Pharmaceutical Co., Ltd. (005500) vs. SPDR S&P 500 ETF (SPY)
Market Cap
₩225.55B
Dividend Yield4.16%
Average Volume (3M)26.84K
Price to Earnings (P/E)10.3
Beta (1Y)0.10
Revenue Growth0.28%
EPS Growth16.80%
CountryKR
Employees819
SectorGeneral
Sector StrengthN/A
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)1869.46
Shares Outstanding13,320,000
10 Day Avg. Volume36,892
30 Day Avg. Volume26,845
Financial Highlights & Ratios
PEG Ratio-0.27
Price to Book (P/B)0.83
Price to Sales (P/S)0.78
P/FCF Ratio24.30
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)1,716
Revenue Forecast (FY)₩315.30B
Samjin Pharmaceutical Co., Ltd. Business Overview & Revenue Model
Company Description
Samjin Pharmaceuticals Co., Ltd. is a South Korean company focused on the discovery and development of pharmaceutical products. Their current portfolio includes SA001, a Phase II clinical asset targeting dry eye and Sjögren's syndrome. In the prec...
Samjin Pharmaceutical Co., Ltd. Financial Statement Overview
Summary
Income Statement
62
Positive
Balance Sheet
70
Positive
Cash Flow
58
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 311.37B | 309.13B | 308.35B | 292.13B | 274.03B | 250.07B |
| Gross Profit | 142.08B | 153.03B | 128.97B | 145.89B | 117.73B | 117.83B |
| EBITDA | 19.15B | 44.50B | 65.92B | 36.60B | 36.81B | 42.41B |
| Net Income | 23.26B | 24.17B | 39.23B | 18.91B | 21.89B | 28.40B |
Balance Sheet | ||||||
| Total Assets | 476.87B | 470.53B | 425.17B | 419.90B | 406.56B | 332.50B |
| Cash, Cash Equivalents and Short-Term Investments | 20.88B | 12.91B | 3.71B | 4.01B | 4.66B | 11.71B |
| Total Debt | 129.88B | 135.89B | 121.42B | 118.64B | 87.51B | 54.51B |
| Total Liabilities | 177.08B | 180.14B | 163.51B | 154.54B | 130.69B | 98.33B |
| Stockholders Equity | 298.77B | 290.39B | 261.66B | 265.36B | 275.34B | 234.17B |
Cash Flow | ||||||
| Free Cash Flow | 25.92B | 9.96B | 19.81B | -12.39B | -18.20B | -50.64B |
| Operating Cash Flow | 33.83B | 22.23B | 38.15B | 8.33B | 17.29B | 23.97B |
| Investing Cash Flow | -21.01B | -24.99B | -18.37B | -18.25B | -70.06B | -71.56B |
| Financing Cash Flow | -4.14B | 11.42B | -18.77B | 9.97B | 47.16B | 36.62B |
Samjin Pharmaceutical Co., Ltd. Technical Analysis
Neutral
―
Price Trends
18815.40
Positive
18595.10
Positive
18855.70
Positive
Market Momentum
142.80
Positive
51.04
Neutral
35.52
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For KR:005500, the sentiment is Neutral. The current price of undefined is equal to the 20-day moving average (MA) of 19395.50, equal to the 50-day MA of 18815.40, and equal to the 200-day MA of 18855.70, indicating a neutral trend. The MACD of 142.80 indicates Positive momentum. The RSI at 51.04 is Neutral, neither overbought nor oversold. The STOCH value of 35.52 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for KR:005500.
Samjin Pharmaceutical Co., Ltd. Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
66 Neutral | ₩225.55B | 10.30 | ― | 4.16% | 0.28% | 16.80% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
52 Neutral | ₩212.70B | 59.83 | ― | 0.44% | 11.35% | 204.54% | |
52 Neutral | ₩299.64B | 12.56 | ― | 1.57% | 5.50% | -26.11% | |
50 Neutral | ₩369.99B | 64.89 | ― | 3.33% | 22.17% | -38.54% | |
50 Neutral | ₩169.19B | 63.80 | ― | 3.22% | 1.83% | -67.89% | |
40 Underperform | ₩173.93B | -28.12 | ― | ― | 0.60% | -6964.46% |
* General Sector Average
KR:005500
Samjin Pharmaceutical Co., Ltd.
19,240.00
174.53
0.92%
KR:003000
Bukwang Pharmaceutical Co., Ltd.
3,750.00
95.20
2.60%
KR:003220
Daewon Pharmaceutical Co., Ltd
7,760.00
-5,120.31
-39.75%
KR:003520
YUNGJIN PHARM. CO. LTD
951.00
-1,089.00
-53.38%
KR:004310
Hyundai Pharmaceutical Co., Ltd.
6,880.00
3,159.39
84.92%
KR:009290
Kwang Dong Pharmaceutical Co., Ltd.
6,370.00
567.55
9.78%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.